Pfizer’s takeover bid for AstraZeneca has many blockbuster components, not least a potential price tag of $100 billion and the creation of a pharmaceuticals juggernaut with drugs that treat most of the world’s major illnesses.. But it is the smaller—even seemingly boring—details that could make or break the deal, including a new U.K. tax law that has caught the eye of Pfizer Chief Executive Ian Read.. “The United Kingdom has created attractive incentives for companies to manufacture products and maintain and protect intellectual property, and we have seen that capital and jobs have followed these types of incentives,” Mr. Read said in a Monday-morning statement designed to woo Astra shareholders.